Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Letai

Showing results (81-90 of 182) with videos related to

Pageof 19
Sort By:
Oncotarget|February 11, 2016
Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell linesBrian Koss, Jeremy Ryan, Amit Budhraja, et al.
Cell|October 16, 2012
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AMLThanh-Trang Vo, Jeremy Ryan, Ruben Carrasco, et al.
Breast Cancer Research : BCR|August 6, 2021
Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancerJessica Castrillon Lal, Madeline G Townsend, Anita K Mehta, et al.
Blood|October 17, 2018
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCLKamil Bojarczuk, Kirsty Wienand, Jeremy A Ryan, et al.
Cancer Research|July 14, 2021
Cell Line-Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug CombinationsJorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 18, 2018
Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cellsRaheleh Rezaei Araghi, Gregory H Bird, Jeremy A Ryan, et al.
The Journal of Clinical Investigation|September 7, 2016
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemiaPatrick D Bhola, Brenton G Mar, R Coleman Lindsley, et al.
Leukemia|May 5, 2022
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2021
Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restorationFrancisco J Sánchez-Rivera, Jeremy Ryan, Yadira M Soto-Feliciano, et al.
Cell Death and Differentiation|February 19, 2026
What does BCL-2 do? From new molecular insights to the clinical implicationsCarlo M Croce, Stephen W G Tait, Ana J Garcia-Sáez, et al.
Pageof 19

Showing results (81-90 of 182) with videos related to

Sort By:
Pageof 19
Oncotarget|February 11, 2016
Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell linesBrian Koss, Jeremy Ryan, Amit Budhraja, et al.
Cell|October 16, 2012
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AMLThanh-Trang Vo, Jeremy Ryan, Ruben Carrasco, et al.
Breast Cancer Research : BCR|August 6, 2021
Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancerJessica Castrillon Lal, Madeline G Townsend, Anita K Mehta, et al.
Blood|October 17, 2018
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCLKamil Bojarczuk, Kirsty Wienand, Jeremy A Ryan, et al.
Cancer Research|July 14, 2021
Cell Line-Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug CombinationsJorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 18, 2018
Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cellsRaheleh Rezaei Araghi, Gregory H Bird, Jeremy A Ryan, et al.
The Journal of Clinical Investigation|September 7, 2016
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemiaPatrick D Bhola, Brenton G Mar, R Coleman Lindsley, et al.
Leukemia|May 5, 2022
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2021
Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restorationFrancisco J Sánchez-Rivera, Jeremy Ryan, Yadira M Soto-Feliciano, et al.
Cell Death and Differentiation|February 19, 2026
What does BCL-2 do? From new molecular insights to the clinical implicationsCarlo M Croce, Stephen W G Tait, Ana J Garcia-Sáez, et al.
Pageof 19